

# Jennifer N Brudno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6178366/publications.pdf>

Version: 2024-02-01

19  
papers

5,411  
citations

759233

12  
h-index

839539

18  
g-index

21  
all docs

21  
docs citations

21  
times ranked

6149  
citing authors

#	ARTICLE	IF	CITATIONS
1	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. Critical Care Medicine, 2022, 50, 81-92.	0.9	13
2	Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. Leukemia and Lymphoma, 2022, 63, 1849-1860.	1.3	14
3	Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. Journal of Infectious Diseases, 2022, 225, 1118-1123.	4.0	62
4	Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience. Leukemia and Lymphoma, 2022, 63, 2469-2473.	1.3	6
5	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e246-e265.	3.8	27
6	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood, 2021, 138, 3837-3837.	1.4	8
7	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine, 2020, 26, 270-280.	30.7	182
8	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	2.2	31
9	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
10	Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. Blood, 2020, 136, 50-51.	1.4	14
11	Effects of starting cellular material composition on chimeric antigen receptor T cell expansion and characteristics. Transfusion, 2019, 59, 1755-1764.	1.6	26
12	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
13	Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Reviews, 2019, 34, 45-55.	5.7	570
14	Chimeric antigen receptor T-cell therapies for lymphoma. Nature Reviews Clinical Oncology, 2018, 15, 31-46.	27.6	391
15	Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR. Blood, 2018, 132, 697-697.	1.4	7
16	Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.. Journal of Clinical Oncology, 2018, 36, 3052-3052.	1.6	6
17	Toxicities of chimeric antigen receptor T cells: recognition and management. Blood, 2016, 127, 3321-3330.	1.4	1,019
18	T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood, 2016, 128, 1688-1700.	1.4	626

#	ARTICLE	IF	CITATIONS
19	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 1112-1121.	1.6	513